$12.19
1.75% yesterday
Nasdaq, Dec 24, 10:33 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Target price 2025 - Analyst rating & recommendation

CorMedix Inc Classifications & Recommendation:

Buy
92%
Hold
8%

CorMedix Inc Price Target

Target Price $20.40
Price $12.19
Potential
Number of Estimates 9
9 Analysts have issued a price target CorMedix Inc 2026 . The average CorMedix Inc target price is $20.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend CorMedix Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CorMedix Inc stock has an average upside potential 2026 of . Most analysts recommend the CorMedix Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 43.47 316.43
627.93%
EBITDA Margin -50.72% 58.29%
214.91%
Net Margin -41.25% 61.88%
250.02%

9 Analysts have issued a sales forecast CorMedix Inc 2025 . The average CorMedix Inc sales estimate is

$316m
Unlock
. This is
47.66% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$331m 54.60%
Unlock
, the lowest is
$297m 38.60%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $43.5m
2025
$316m 627.93%
Unlock
2026
$446m 40.95%
Unlock
2027
$424m 5.01%
Unlock
2028
$481m 13.64%
Unlock
2029
$507m 5.32%
Unlock
2030
$567m 11.75%
Unlock
2031
$705m 24.47%
Unlock
2032
$791m 12.12%
Unlock

3 Analysts have issued an CorMedix Inc EBITDA forecast 2025. The average CorMedix Inc EBITDA estimate is

$184m
Unlock
. This is
70.48% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$190m 75.49%
Unlock
, the lowest is
$177m 63.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-22.1m 54.90%
2025
$184m 936.55%
Unlock
2026
$267m 44.85%
Unlock

EBITDA Margin

2024 -50.72%
2025
58.29% 214.91%
Unlock
2026
59.91% 2.78%
Unlock

9 CorMedix Inc Analysts have issued a net profit forecast 2025. The average CorMedix Inc net profit estimate is

$196m
Unlock
. This is
20.49% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$241m 48.33%
Unlock
, the lowest is
$147m 9.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-17.9m 61.31%
2025
$196m 1,192.02%
Unlock
2026
$197m 0.84%
Unlock
2027
$174m 12.01%
Unlock
2028
$240m 37.99%
Unlock
2029
$262m 9.33%
Unlock
2030
$324m 23.78%
Unlock
2031
$370m 14.04%
Unlock
2032
$408m 10.37%
Unlock

Net Margin

2024 -41.25%
2025
61.88% 250.02%
Unlock
2026
44.27% 28.46%
Unlock
2027
41.01% 7.36%
Unlock
2028
49.80% 21.43%
Unlock
2029
51.70% 3.82%
Unlock
2030
57.26% 10.75%
Unlock
2031
52.46% 8.38%
Unlock
2032
51.64% 1.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.30 2.50
67.03% 933.33%
P/E 4.88
EV/Sales 3.32

9 Analysts have issued a CorMedix Inc forecast for earnings per share. The average CorMedix Inc EPS is

$2.50
Unlock
. This is
32.98% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$3.08 63.83%
Unlock
, the lowest is
$1.87 0.53%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.30 67.03%
2025
$2.50 933.33%
Unlock
2026
$2.52 0.80%
Unlock
2027
$2.22 11.90%
Unlock
2028
$3.06 37.84%
Unlock
2029
$3.35 9.48%
Unlock
2030
$4.14 23.58%
Unlock
2031
$4.72 14.01%
Unlock
2032
$5.21 10.38%
Unlock

P/E ratio

Current 6.48 160.53%
2025
4.88 24.74%
Unlock
2026
4.84 0.82%
Unlock
2027
5.50 13.64%
Unlock
2028
3.98 27.64%
Unlock
2029
3.64 8.54%
Unlock
2030
2.94 19.23%
Unlock
2031
2.58 12.24%
Unlock
2032
2.34 9.30%
Unlock

Based on analysts' sales estimates for 2025, the CorMedix Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.90 87.33%
2025
3.32 32.26%
Unlock
2026
2.36 29.06%
Unlock
2027
2.48 5.28%
Unlock
2028
2.18 12.00%
Unlock
2029
2.07 5.05%
Unlock
2030
1.85 10.51%
Unlock
2031
1.49 19.66%
Unlock
2032
1.33 10.80%
Unlock

P/S ratio

Current 4.48 89.43%
2025
3.04 32.28%
Unlock
2026
2.15 29.05%
Unlock
2027
2.27 5.28%
Unlock
2028
1.99 12.00%
Unlock
2029
1.89 5.05%
Unlock
2030
1.70 10.51%
Unlock
2031
1.36 19.66%
Unlock
2032
1.21 10.80%
Unlock

Current CorMedix Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Dec 18 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 13 2025
D. Boral Capital
Locked
Locked
Locked Nov 12 2025
Needham
Locked
Locked
Locked Nov 12 2025
RBC Capital
Locked
Locked
Locked Oct 21 2025
D. Boral Capital
Locked
Locked
Locked Oct 20 2025
JMP Securities
Locked
Locked
Locked Sep 09 2025
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Dec 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 13 2025
Locked
D. Boral Capital:
Locked
Locked
Nov 12 2025
Locked
Needham:
Locked
Locked
Nov 12 2025
Locked
RBC Capital:
Locked
Locked
Oct 21 2025
Locked
D. Boral Capital:
Locked
Locked
Oct 20 2025
Locked
JMP Securities:
Locked
Locked
Sep 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today